Table 2.

Effects of the MELD score and the follow-up period on the percentages of lymphocyte subpopulations following liver transplantation.

Percentages	LmLf (n = 18)	HmLf (n = 13)	LmSf (n = 20)	HmSf (n = 15)
T	63.90 ± 10.52	61.89 ± 16.81*	57.22 ± 13.29*	38.35 ± 27.06
TCD4	32.06 ± 8.06	28.09 ± 14.85*	26.24 ± 10.23*	16.33 ± 13.30
TCD8	31.97 ± 6.52	33.84 ± 13.28*	30.93 ± 9.98*	22.09 ± 15.30
B	7.73 ± 8.56	6.32 ± 6.62	6.25 ± 4.88*	2.74 ± 2.69
NK	12.31 ± 4.82	13.02 ± 6.73	11.76 ± 6.73	10.03 ± 9.06

MELD, model for end-stage liver disease; T, CD3⁺ T cells; TCD4, CD3⁺ CD4⁺ T cells; TCD8, CD3⁺ CD8⁺ T cells; B, CD19⁺ B cells; NK, CD56⁺ CD16⁺ natural killer cells; Lm, low MELD score; Hm, high MELD score; Sf, short-term follow-up; Lf, long-term follow-up.

HmLf vs. HmSf, LmSf vs. HmSf,

^*p < 0.05.